Complejo Hospitalario Universitario de Badajoz
Badajoz, 06080, Spain
Location status: Recruiting
NCT Number: NCT06607445
An open longitudinal observational study, non-randomized, which will include the adult population, attended by the SES, in which preference will be given to those patients under treatment with drugs that can produce relevant adverse effects. It is a naturalistic study in which no pharmacological or other type of intervention will be carried out, only the information recommended in the drug data sheet (pharmacogenetic biomarkers, relevant interactions and clinical contraindications) will be provided.
Interested in participating?
Request InfoAll sexes
Observational
Badajoz, 06080, Spain
Location status: Recruiting
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patients with a recent diagnosis and who are to be or are being treated according to usual clinical practice, who meet the criteria to participate in the study, read the corresponding information sheet, sign informed consent and agree to participate, provided they meet the following inclusion criteria:
General criteria for all patients:
Exclusion criteria
Time frame: December 2024
To analyze the implementation in the clinical routine of a pharmacogenetics and personalized medicine program in SES patients, evaluating the overall impact on the health system, and at the individual level, general modifications in the clinical response and its temporal evolution.
Complejo Hospitalario Universitario de Badajoz
Other
Evaluation of the Implementation of the Pharmacogenetics and Personalized Medicine Program "MedeA" in the Extremadura Health Service. Population Cohort [MedeA21].
Acronym: MedeA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06575530
Adverse Drug Event, Chemically-Induced Disorders
Beijing, Beijing Municipality, China
View Trial DetailsNCT05512169
ALL, Childhood, Adverse Drug Event
New Delhi, India
View Trial DetailsNCT05084196
Acute Kidney Injury, Adverse Drug Event
New Brunswick, New Jersey, United States
View Trial DetailsNCT07164300
Adverse Drug Event, Blood Coagulation Disorder
Ioannina, Greece
View Trial Details